Kamlesh Khunti (FRCGP, FRCP, MD, PhD, FMedSci) undertook his medical training at the University of Dundee. He is Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester and Leicester General Hospital, UK. He is also co-director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have or are at increased risk of developing cardiometabolic diseases. His wider research interests focus on primary care and public health, ethnic health; cardiometabolic diseases, multiple long term conditions and pragamatic interventional studies real-world evidence.
Professor Khunti has published more than 1200 articles, including a large number on COVID-19. His work has influenced national and international guidelines on the screening and management of people with diabetes He is a member of the UK’s Scientific Advisory Group for Emergency (SAGE) and Chair of the Ethnicity Subgroup of SAGE.
Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations East Midlands and Director of the Real-world Evidence Unit and Centre for Ethnic Health Research. He is a Senior Investigator and principal investigator on several major national and international studies. He is the National NIHR ARC Theme Lead for Multiple Long Term Condtions and Ethnicity and Diversity. He is also Honorary Visiting Professorial Fellow with Department of General Practice, University of Melbourne.
Professor Khunti is also a Fellow of the Academy of Medical Sciences and is currently an advisor to the Department of Health, a Clinical Advisor for the National Institute for Health and Care Excellence (NICE)He is Member of the KDIGO Diabetes and CKD Guideline Group and a member of the American Diabetes Association Standards of Care Guidelines for Diabetes. He is past chair of the NICE Guidelines on Prevention of Diabetes. He has won numerous awards nationally and internationally and was awarded the Commander of the Order of the British Empire (CBE) in the 2022 New Year’s Honour’s List for services to health.
Duality of Interest: Professor Khunti has received research grants / supports from AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche and Sanofi and speaker’s Honorarium / fees from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche and Sanofi. He has also received consultancy payments form Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi and Servier.
Date: Summer 2023